Search - tctmd.com

Displaying 61 - 80 of 374

Sort: Relevancy | Date

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

February 13, 2024

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

News Daily News

BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes

February 02, 2024

DOAC Don’ts New Review Clarifies When Not to Use Direct Oral Anticoagulants

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

January 17, 2024

Top Heart Rhythm News of 2023

News Daily News

Top Heart Rhythm News of 2023

December 26, 2023

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

News Daily News

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

November 30, 2023

Outcomes Suffer When Device-Related Thrombus Persists or Recurs After LAAO

News Daily News

Outcomes Suffer When Device-Related Thrombus Persists or Recurs After LAAO

November 29, 2023

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

News Daily News

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

Michael O'Riordan

November 27, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial -

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

News Conference News AHA 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

November 14, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Younger Age at AF Onset Linked to Greater Dementia Risk

News Daily News

Younger Age at AF Onset Linked to Greater Dementia Risk

Yael L. Maxwell

November 10, 2023

Percutaneous Left Atrial Appendage Closure Versus Chronic Oral Anticoagulation for Non-Valvular Atrial Fibrillation: An Individual Patient Data Level Meta-Analysis of Randomized Controlled Trials

Presentation TCT 2023

Percutaneous Left Atrial Appendage Closure Versus Chronic Oral Anticoagulation for Non-Valvular Atrial Fibrillation: An Individual Patient Data Level Meta-Analysis of Randomized Controlled Trials

Presenter: Yousif Ahmad

October 25, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

One-Third of Patients With AF After Surgery or Illness Have Recurrences

News Daily News

One-Third of Patients With AF After Surgery or Illness Have Recurrences

Michael O'Riordan

October 02, 2023

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

September 18, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

TCTMD’s Top 10 Most Popular Stories for August 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2023

September 04, 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.